Genomic analyses of pancreatic cancer have revealed a mutational landscape with four common oncogenic events in KRAS, TP53, SMAD4 and CDKN2A, among which KRAS mutations are the most frequent being found in up to 90% of tumors (6,7). This evidence concerns the gene KRAS and pancreatic neoplasm.